Anal cancer and immunotherapy-are we there yet?
- PMID: 31559338
- PMCID: PMC6737437
- DOI: 10.21037/tgh.2019.08.02
Anal cancer and immunotherapy-are we there yet?
Conflict of interest statement
Conflicts of Interest: Dr. K Almhanna has a consulting agreement with Merck. JJ Bian has no conflicts of interest to declare.
Comment on
-
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.Ann Oncol. 2017 May 1;28(5):1036-1041. doi: 10.1093/annonc/mdx029. Ann Oncol. 2017. PMID: 28453692 Free PMC article. Clinical Trial.
References
-
- Islami F, Ferlay J, Lortet-Tieulent J, et al. International trends in anal cancer incidence rates. Int J Epidemiol 2017;46:924-38. - PubMed
-
- Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996;14:2527-39. 10.1200/JCO.1996.14.9.2527 - DOI - PubMed
-
- Amin MB, Edge S, Greene F, et al. AJCC Cancer Staging Manual. 8th edition. Chicago, IL: Springer International Publishing, 2017:280.
Publication types
LinkOut - more resources
Full Text Sources